5-amino-1MQ for fat loss: mouse data, no human trials

The short answer: 5-amino-1MQ has never been tested in people. In mice with diet-induced obesity, an inhibitor of the enzyme NNMT from this chemical series reduced body weight and white fat mass, and that is the basis for its fat loss reputation. [1] No human study of 5-amino-1MQ of any kind, for fat loss, safety, or absorption, has been published. It also has no lawful access path in the United States.

One more thing is often missed: 5-amino-1MQ is not a peptide. It is a small molecule, a methylquinolinium compound, that is marketed alongside peptides. [1]

This page covers what the mouse studies found, the capsule versus injection question, what is known about side effects, and legal status. It does not give dosing, and no human dose has been established.

How is 5-amino-1MQ supposed to work?

5-amino-1MQ blocks nicotinamide N-methyltransferase (NNMT), an enzyme that uses the methyl donor SAM to methylate nicotinamide, a form of vitamin B3 and a building block of NAD+. A 2014 study found NNMT expression was raised in the fat tissue and liver of obese and diabetic mice, and that knocking NNMT down protected mice from diet-induced obesity by increasing energy expenditure. [2] Blocking the enzyme raised SAM and NAD+ in fat tissue. [2] That made NNMT a drug target, and 5-amino-1MQ is one of the inhibitors developed against it.

Does 5-amino-1MQ work for fat loss? The mouse studies

Three mouse treatment studies make up the fat loss evidence, and a fourth line of genetic research complicates it.

1. 2018, the founding study. Obese mice on a high-fat diet treated with a potent inhibitor from the methylquinolinium series lost body weight and white fat mass, had smaller fat cells and lower cholesterol, and did not eat less. The authors reported no observable adverse effects. [1]
2. 2024, 28 days of treatment. 5-amino-1MQ limited weight and fat mass gain in a dose-dependent way, improved glucose tolerance and insulin sensitivity, and reduced fatty liver in diet-induced obese mice. [3]
3. 2022, with a diet change. Combined with a switch to a low-fat diet, the inhibitor rapidly normalized adiposity and body weight in obese mice to lean levels, which the diet switch alone did not do in the same time frame. [4]
4. Genetic evidence is mixed. Mice bred without NNMT did not reproduce every benefit: knockout males had better insulin sensitivity on a high-fat diet but no better glucose tolerance, and in a human weight reduction study, NNMT expression in fat actually increased during weight loss. [7]

Several of these papers come from authors who founded or work for a company developing NNMT inhibitors, which they disclose. [3] That does not make the results wrong, but none has been independently replicated in people.

The fat loss condition page and the obesity condition page rank 5-amino-1MQ against options with human trials, and our peptides for weight loss ranking places it among every compound we grade.

Muscle claims: aged mice only

Some marketing pairs fat loss with muscle claims. In 24 month old mice, an NNMT inhibitor activated muscle stem cells and improved muscle regeneration after injury. [5] In a 2024 study, aged sedentary mice given the inhibitor had about 40% greater grip strength than untreated controls, and the effect added to that of exercise. [6] These results are in old mice recovering from injury or inactivity, not in people, and not in younger adults seeking muscle growth.

5-amino-1MQ capsules vs injection

Most products are sold as oral capsules. The only direct data on routes come from mice: a 2024 study measured blood and tissue levels after intravenous, oral, and subcutaneous dosing, and reported high systemic exposure and good distribution to fat, muscle, and liver after subcutaneous dosing. [3] Earlier laboratory tests found that compounds in this series cross cell membranes well. [1]

No study has measured how much 5-amino-1MQ reaches the bloodstream from a capsule in a person, and no study has compared oral with injected use in people. Any claim that one form "works better" is not based on human data.

5-amino-1MQ side effects: the missing human safety data

There are no published human safety data. What is known:

• In mice, the founding obesity study reported no observable adverse effects over a short treatment period. [1]
• Mechanism-based unknowns: NNMT sits at the junction of NAD+ metabolism and the SAM methyl-donor pool, and blocking it changed histone methylation in mouse fat tissue. [2] What long-term inhibition does to those systems in people has not been studied.
• No long-term toxicology in any species has been published. Side effects reported online, such as nausea or headache, are anecdotes from unverified products.

Anyone taking medicines for diabetes should be aware that the mouse studies reported improved insulin sensitivity, but no study has tested 5-amino-1MQ alongside glucose-lowering drugs. [3]

Why mouse fat loss results often do not carry over

Diet-induced obese mice are a standard first test for obesity drugs, and many compounds that work in them never reach approval. Mice differ from people in metabolic rate, fat distribution, and how they process drugs, and short studies cannot show whether weight loss lasts or what happens when treatment stops. The genetic NNMT studies already show that the biology is less tidy than the first results suggested: removing the enzyme did not reproduce every benefit, and in people losing weight, NNMT in fat went up rather than down. [7] That is why our methodology grades 5-amino-1MQ animal only, the same grade we give any compound without a controlled human study.

How does it compare with AOD-9604 and NAD+?

5-amino-1MQ is often grouped with other weak-evidence fat loss compounds. Our AOD-9604 vs 5-amino-1MQ comparison sets their evidence side by side. Because NNMT inhibition raises cellular NAD+ in mice, it is also discussed alongside NAD+, though the two have not been tested together. [2]

Is 5-amino-1MQ legal?

5-amino-1MQ is not an FDA approved drug and is not an ingredient in any approved drug. It is not on the 503A bulks list, and it has no USP monograph, so it meets none of the three criteria a 503A pharmacy needs to compound from a bulk substance. [8] It does not appear on FDA's Category 2 list or among active nominations. [9] That leaves no lawful basis for a pharmacy to dispense it, despite wide marketing as a compounded capsule. Products labeled for research use are not lawful for human use and are not verified for identity or purity.

Because it is not approved for human use anywhere, it falls under WADA's non-approved substances section for tested athletes. [10]

The 5-amino-1MQ regulatory page records its status, the 5-amino-1MQ cost page explains why there is no lawful price to compare, and the state legal guide covers state rules. If fat loss is the goal, the approved GLP-1 medicines in our GLP-1 hub are the options with large human trials.